Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18375400rdf:typepubmed:Citationlld:pubmed
pubmed-article:18375400lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0151744lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0003851lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0053358lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0162596lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0370188lld:lifeskim
pubmed-article:18375400lifeskim:mentionsumls-concept:C0442821lld:lifeskim
pubmed-article:18375400pubmed:issue5lld:pubmed
pubmed-article:18375400pubmed:dateCreated2008-4-21lld:pubmed
pubmed-article:18375400pubmed:abstractTextThe main objective of this study was to clarify the role of aPLs in the pathogenesis of arteriosclerosis obliterans (ASO), ischaemic heart disease (IHD) and cerebral vascular disorder (CVD) in patients with SLE.lld:pubmed
pubmed-article:18375400pubmed:languageenglld:pubmed
pubmed-article:18375400pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375400pubmed:statusMEDLINElld:pubmed
pubmed-article:18375400pubmed:monthMaylld:pubmed
pubmed-article:18375400pubmed:issn1462-0332lld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:MasudaYYlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:WatanabeYYlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:TakanoTTlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:HidakaYYlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:SuehisaEElld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:KuratsuneHHlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:IwataniYYlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:NojimaJJlld:pubmed
pubmed-article:18375400pubmed:authorpubmed-author:KanakuraYYlld:pubmed
pubmed-article:18375400pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18375400pubmed:volume47lld:pubmed
pubmed-article:18375400pubmed:ownerNLMlld:pubmed
pubmed-article:18375400pubmed:authorsCompleteYlld:pubmed
pubmed-article:18375400pubmed:pagination684-9lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:meshHeadingpubmed-meshheading:18375400...lld:pubmed
pubmed-article:18375400pubmed:year2008lld:pubmed
pubmed-article:18375400pubmed:articleTitleArteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus.lld:pubmed
pubmed-article:18375400pubmed:affiliationLaboratory for Clinical Investigation, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan. nojima@hp-lab.med.osaka-u.ac.jplld:pubmed
pubmed-article:18375400pubmed:publicationTypeJournal Articlelld:pubmed